Skip to main content
. 2012 Apr 13;3(3):345–356. doi: 10.18632/oncotarget.457

Figure 4. GW9662 signaling pathways in tumors from control and GW9662-treated animals.

Figure 4

Pathways are based on the expression of genes that were reduced ≥2.5-fold by GW9662 in Table S1. Metabolic signaling pathways associated with genes that were downregulated by GW9662.